StockWireNews

Nasdaq Low Float Idea (NMRD) Has 5 Must-Know Potential Catalysts To Focus On Right Now (Read Immediately)

September 18th

Greetings Readers,

In the realm of healthcare and wellness, tracking a company determined to disrupt markets of such colossal magnitude is not just important; it's imperative.

And one specific Nasdaq traded company's actions could start garnering Wall Street's attention in a big way.

With a recent Zacks Equity Research "Upgrade," a low float of fewer than 13Mn shares, strong retention rates from a key metabolic health program, and SFDA approval that'll speed up commercialization efforts, this Nasdaq idea needs immediate attention.

Drop everything this second and pull up:

*Nemaura Medical Inc. (NMRD)*

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is currently also commercializing sugarBEAT® and proBEAT™.

And right now, NMRD has several potential catalysts to focus on ahead of Monday's opening bell. Check them out:

No. 1 - Interim Results From Miboko Program Holds Eye-Catching Retention Rates

No. 2 - NMRD's Low Float Suggests Volatile Potential

No. 3 - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)

No. 4 - Corporate Highlights Paint Nemaura To Be Hurtling Towards Bright Future

No. 5 - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)

But more on those in a second...

The Future Of Diagnostic Technology

BEAT® Technology Platform

Convenient, timely and painless, Nemaura's needle-free, patented BEAT® sensor is applied to the skin via a small unobtrusive patch and measures.

Transmitting this data to users and / or healthcare professionals via a Smartphone App, the technology will allow for medical conditions and chronic diseases to be monitored for better disease management or treatment.

Applications of Nemaura's technology include: glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring.

Miboko - Your Health, Your Way

In addition to the medical applications, Nemaura has developed Miboko, (www.Miboko.com), a digital healthcare program with the glucose sensor at its heart.

They believe Miboko addresses a significant mass market opp. that could benefit roughly a third to half of the population by using a non-invasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance.

Those with pre-diabetes or obesity concerns, or even those looking to maintain better health through more careful glucose control, may benefit from such a metabolic health program.

How one’s body metabolizes sugar is the main influencer of one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes), such as heart disease and dementia.

sugarBEAT® - The World’s First Non-invasive Real Time Continuous Glucose System For Everyone

The company’s first product, which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive continuous glucose monitoring (CGM) device and BEAT®diabetes digital healthcare platform.

sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data.

These insights help people with Type 1 or Type 2 diabetes to better manage and reverse their condition and can help those people with pre-diabetes to prevent the onset of diabetes.

BEAT®diabetes is a health subscription service providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized data provided by sugarBEAT®.

Insulin users can also adjunctively use sugarBEAT® for determining the proper insulin dosing when it is calibrated by a finger stick reading.

sugarBEAT® is intended to be worn during waking hours and consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter and an app displaying glucose readings at five-minute intervals.

Grab Key Sources Here: Company Presentation. Company Website.

-----

As mentioned above, NMRD has several potential breakout catalysts to focus on immediately. Take a look:

No. 1 NMRD Potential Catalyst - Interim Results From Miboko Program Holds Eye-Catching Retention Rates

Nemaura Medical Announces Interim Results...

Read the full article here.

-----

No. 2 NMRD Potential Catalyst - NMRD's Low Float Suggests Volatile Potential

According to the Yahoo Finance website, NMRD has a relatively low float.

The website reports this profile to have roughly 12.33Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more positive company news towards the end of 2023 provide a breakout spark?

-----

No. 3 NMRD Potential Catalyst - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)

Nemaura Medical Announces SFDA Approval of sugarBEAT®

Read the full article here.

-----

No. 4 NMRD Potential Catalyst - Corporate Highlights Paint Nemaura To Be Hurtling Towards Bright Future

Nemaura Medical Reports Fi-nan-cial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

From the article:

“We continue to build momentum on both manufacturing activities and consumer feedback through pilot trials, in preparation for scaling up commercial sales activities. The trials with the NHS in the UK have demonstrated the commercial potential for our sensors and digital health and wellbeing programs and has allowed us to undertake continuous refinements prior to commercial scale-up initiatives. Similarly, we believe working with world-class contract manufacturers and advancing our manufacture scale-up, and ensuring a well-managed supply chain through forward planning will support our planned commercial endeavours,” commented Dr Faz Chowdhury, CEO of Nemaura medical. “During the new fiscal year our focus is on global partnerships and revenue ramp-up, leveraging off the progress we have made on the product refinement and feedback, and product manufacture."

Read the full article here.

-----

No. 5 NMRD Potential Catalyst - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT™ sensor and AI-based feedback platform, augmenting the BEAT™diabetes program. The pilots are intended as a precursor to revenue generating contracts for proBEAT™ and will commence over the coming weeks and months. The Company is continuing its discussions with corporations and health insurers in the U.S. to further increase the number of pilots that will run in calendar year 2023.

...

Read the full article here.

-----

NMRD Recap - 5 Key Potential Catalysts To Watch Right Now

No. 1 - Interim Results From Miboko Program Holds Eye-Catching Retention Rates

No. 2 - NMRD's Low Float Suggests Volatile Potential

No. 3 - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)

No. 4 - Corporate Highlights Paint Nemaura To Be Hurtling Towards Bright Future

No. 5 - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)

-----

Coverage is officially initiated on NMRD. When time allows, do this:

Get NMRD on your radar right now.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)